- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07642687
Near Vergence Training for Distance Control in Intermittent Exotropia
Evaluating Near Vergence Training for Distance Control in Basic and Divergence Excess Intermittent Exotropia
Intermittent Exotropia (IXT) is a common type of eye misalignment where one eye periodically turns outward, and control is typically much worse when looking at objects far away than close up. However, most currently available training programme are focused on near-viewing tasks. The goal of this clinical trial is to investigate if a new, structured, home-based near eye training program works to improve distance eye alignment control in children and young adults with IXT.
The main questions the study aims to answer are:
- Does a 12-week near eye training program improve a participant's ability to control their eye alignment when looking at a distance?
- Does using a special reading glasses during near training help to control distance eye alignment better than doing the training without the reading glasses?
- Do the benefits of this eye training last after the training has stopped?
This is a two- phase, single- masked (examiner masked), randomized clinical trial with crossover design. The entire study duration is about 24 weeks. A total sample size of 42 participants, aged 6 to 25 years with diagnosed Basic (distance deviation is within 10 prism diopters of the near deviation) or Divergence excess (distance deviation is at least 10 prism diopters greater than the near deviation) IXT, will be recruited.
In Phase I (Weeks 0 to 12), participants will be randomly allocated into one of three groups, with 14 individuals in each group:
- Group 1 does eye training while wearing special plus-power reading glasses that remove the need to focus up close, mimicking how the eyes look at a distance.
- Group 2 does the exact same eye training but wears regular distance glasses without the special reading addition.
- Group 3 serves as a control group that does not do training during the first 12 weeks, but will receive the training in the second phase.
In Phase II (Weeks 13 to 24), which is a crossover phase, groups 1 and 2 will stop training to see if the visual improvements last, while group 3 will be re-randomized into two subgroups (group 3A, with special plus-power reading glasses, and group 3B with regular glasses with distance correction) that will undertake daily eye training for 12 weeks to ensure ethical treatment access. All participants will have a final eye exam at 24 weeks.
During home training, participants will:
- Wear standard glasses provided by the study.
- Practice daily, home-based eye exercises for 12 weeks using a standardized software program on a computer or tablet.
- Complete 3 training sessions every day, lasting 7 minutes per session.
- Wear red-blue 3D glasses during training and press arrow keys or swipe the screen to play a visual game that dynamically changes in difficulty.
Preliminary test and binocular vision assessment with fixed and uniform sequence will be performed at baseline visit, 6th week interim visit, 12th and 24th week evaluation. All eye examinations will be carried out in The Optometry Centre (A034), the School of Optometry, The Hong Kong Polytechnic University.
The following data will be statistically analyzed. The primary outcome data is distance Office Control Score (OCS) at 12-week visit. Secondary outcomes data include change in deviation angle, near and distance stereopsis and patient- / parent- reported health-related quality-of-life questions at 12-week.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Horace Ho-yin Wong, MClinOptom, BSc (Hons) Optom
- Numéro de téléphone: 852-63384048
- E-mail: horace.wong@polyu.edu.hk
Sauvegarde des contacts de l'étude
- Nom: Tsz Wing Leung, PhD
- Numéro de téléphone: 852- 27664268
- E-mail: jeffrey.TW.leung@polyu.edu.hk
Lieux d'étude
-
-
-
Hong Kong, Hong Kong
- Recrutement
- The Optometry Clinic, The Hong Kong Polytechnic University
-
Contact:
- Horace Ho-yin Wong, MClinOptom, BSc (Hons) Optom
- Numéro de téléphone: 852-63384048
- E-mail: horace.wong@polyu.edu.hk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
-
Age and Diagnosis: Participants must be aged 6 to ≤ 25 years at the time of screening, with a confirmed clinical diagnosis of either Basic or Divergence Excess (DE) Intermittent Exotropia (IXT).
-
Ocular Alignment Magnitude: Distance exodeviation measuring between 10 and 40 prism diopters (pd) inclusive, determined by the prism and alternate cover test (PACT).
-
Distance-Near Disparity Limits: Near exodeviation must not exceed the distance exodeviation by more than 10 pd (to exclude Convergence Insufficiency type exotropia).
-
Baseline Distance Control: A baseline distance IXT Office Control Score (OCS) between Grade 2 and Grade 4 inclusive, based on the mean of 3 standardized assessments.
-
Baseline Near Control: A baseline near IXT control score less than or equal to the distance IXT control score, based on the mean of 3 standardized assessments.
-
Visual Acuity: Best-corrected visual acuity (BCVA) of Logarithm of the Minimum Angle of Resolution (logMAR) 0.1 or better in each eye at both distance and near fixation.
-
Sensory Status: Measurable near stereoacuity of 400 arc seconds or better on the Preschool Randot stereoacuity test.
-
Refractive Correction Stability: Compliance with wearing a stable, appropriate spectacle correction for ≥ 4 months prior to formal baseline assessment if the participant meets any of the following refractive thresholds:
- Myopia < -0.50D spherical equivalent (SE) in either eye.
- Hyperopia > +2.50D SE in either eye.
- Anisometropia > 1.00 SE.
- Astigmatism > 1.50D cylinder in either eye.
-
Treatment History: No history of prior non-surgical interventions for IXT, including patching, vision therapy/orthoptics, or overminus lens therapy (≥ 0.50 D).
-
Surgical History: No prior history of strabismus surgery, extraocular muscle botulinum toxin injections, intraocular surgery, or refractive surgery.
-
Trial Commitment: No planned strabismus surgery or conflicting ocular therapies during the 24-week study period.
Exclusion Criteria
- Amblyopia and Co-morbid Strabismus: Presence of amblyopia, nystagmus, restrictive strabismus, or paretic strabismus.
- Vertical Misalignment: Presence of an associated vertical ocular deviation > 5 pd.
- Significant Pathologies: Co-existing significant ocular disease or neurological disorders (e.g., cerebral palsy) that could confound oculomotor or sensory evaluations.
- Confounding Medications: Regular use of systemic or topical ocular medications known to alter accommodative or vergence function within the 3 months prior to screening (including, but not limited to, atropine, pirenzepine, or systemic anti-epileptic agents).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Active training group with reading glasses
Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence |
Standardized home-based near vergence training platform with data visualization tools and communication platforms |
|
Comparateur actif: Active training group without reading glasses
Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence |
Standardized home-based near vergence training platform with data visualization tools and communication platforms |
|
Aucune intervention: Control group
No training will be received in Phase I (Weeks 0 to 12); Will receive training in Phase II of the study (Weeks 13 to 24) to ensure ethical treatment access |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change of Distance Office Control Score
Délai: Baseline, 6-week, 12-week and 24-week
|
Objective and quantitative office control scale, based on the frequency of deviation and the recovery speed followed by occlusion. Ranged from 0 to 5, with score 0 represents the best control (phoria with excellent control), and score 5 represents the worst control (constant exotropia during the 30-second observation) |
Baseline, 6-week, 12-week and 24-week
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change of exodeviation magnitude angle
Délai: Baseline, 6-week, 12-week and 24-week
|
measured by Prism and Alternate Cover Test, ranged from 1 to 50 prism diopter. The higher the value, the worse is the magnitude angle of the exodeviation |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Distance stereoacuity
Délai: Baseline, 6-week, 12-week and 24-week
|
measured by Distance Randot® stereotest, ranged from 400 seconds of arc (the worst measurable stereoacuity) to 60 seconds of arc (the best measurable stereoacuity ) |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Near stereoacuity
Délai: Baseline, 6-week, 12-week and 24-week
|
measured by Preschool Randot® stereoacuity test, ranged from 800 seconds of arc (the worst measurable stereoacuity) to 40 seconds of arc (the best measurable stereoacuity ) |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Quality of Life (QoL) measures - Chinese Intermittent Exotropia Questionnaire (CIXTQ) for children aged 5 to 17 and parents of children aged 2 to 17
Délai: Baseline, 12-week and 24-week
|
Part a: Child CIXTQ - 12 items completed by children, simplified 3-point scale (0, 50 and 100); Part b: Proxy CIXTQ - 12 items completed by parents to evaluate their child's health-related quality-of-life (HRQoL) from a parental perspective, 5-point Likert-type (0, 25, 50, 75, and 100); Part c: Parent CIXTQ - 17 items to measure the parent's own HRQoL, 5-point Likert-type (0, 25, 50, 75 and 100). The higher the score, the better the outcome (QoL). |
Baseline, 12-week and 24-week
|
|
Change of Quality of Life (QoL) measures - The Chinese Adult Strabismus Quality of Life Questionnaire (CAS-20) for adult participants aged 18 or above
Délai: Baseline, 12-week and 24-week
|
20 items to assess psychosocial impact and visual function, 5-point Likert-type (0, 25, 50, 75 and 100). Higher scores indicating better perceived QoL. |
Baseline, 12-week and 24-week
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Mohney BG, Holmes JM. An office-based scale for assessing control in intermittent exotropia. Strabismus. 2006 Sep;14(3):147-50. doi: 10.1080/09273970600894716.
- Ma MM, Kang Y, Scheiman M, Chen Q, Ye X, Pan L, Deng J, Su G, Zhang G, Chen X. Office-based vergence and anti-suppression therapy for the treatment of small-to-moderate angle intermittent exotropia: A randomised clinical trial. Ophthalmic Physiol Opt. 2024 Mar;44(2):356-377. doi: 10.1111/opo.13264. Epub 2023 Dec 26.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- HSEARS20251213004
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .